JP5399898B2 - 神経因性疼痛の治療用カンナビノイド - Google Patents

神経因性疼痛の治療用カンナビノイド Download PDF

Info

Publication number
JP5399898B2
JP5399898B2 JP2009517376A JP2009517376A JP5399898B2 JP 5399898 B2 JP5399898 B2 JP 5399898B2 JP 2009517376 A JP2009517376 A JP 2009517376A JP 2009517376 A JP2009517376 A JP 2009517376A JP 5399898 B2 JP5399898 B2 JP 5399898B2
Authority
JP
Japan
Prior art keywords
thc
cbd
cbme
pain
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009517376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541479A (ja
JP2009541479A5 (enExample
Inventor
ジェフリー・ガイ
バルバラ・コスタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Operations UK Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of JP2009541479A publication Critical patent/JP2009541479A/ja
Publication of JP2009541479A5 publication Critical patent/JP2009541479A5/ja
Application granted granted Critical
Publication of JP5399898B2 publication Critical patent/JP5399898B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009517376A 2006-06-23 2007-06-21 神経因性疼痛の治療用カンナビノイド Expired - Fee Related JP5399898B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612512.4 2006-06-23
GB0612512A GB2439393B (en) 2006-06-23 2006-06-23 Cannabinoids for use in the treatment of neuropathic pain
PCT/GB2007/002315 WO2007148094A1 (en) 2006-06-23 2007-06-21 Cannabinoids for use in the treatment of neuropathic pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013182318A Division JP2013241471A (ja) 2006-06-23 2013-09-03 神経因性疼痛の治療用カンナビノイド

Publications (3)

Publication Number Publication Date
JP2009541479A JP2009541479A (ja) 2009-11-26
JP2009541479A5 JP2009541479A5 (enExample) 2010-07-29
JP5399898B2 true JP5399898B2 (ja) 2014-01-29

Family

ID=36803806

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009517376A Expired - Fee Related JP5399898B2 (ja) 2006-06-23 2007-06-21 神経因性疼痛の治療用カンナビノイド
JP2013182318A Pending JP2013241471A (ja) 2006-06-23 2013-09-03 神経因性疼痛の治療用カンナビノイド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013182318A Pending JP2013241471A (ja) 2006-06-23 2013-09-03 神経因性疼痛の治療用カンナビノイド

Country Status (8)

Country Link
US (3) US20100016418A1 (enExample)
EP (1) EP2037902B1 (enExample)
JP (2) JP5399898B2 (enExample)
CA (1) CA2656698C (enExample)
ES (1) ES2429406T3 (enExample)
GB (1) GB2439393B (enExample)
PL (1) PL2037902T3 (enExample)
WO (1) WO2007148094A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
ES2534900T3 (es) 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2524689B (en) * 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
GB2524469A (en) * 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
EP3134393B1 (en) * 2014-04-21 2020-12-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cyclohexenyl compounds, compositions comprising them and uses thereof
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
CA2974292C (en) * 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
HK1252151A1 (zh) 2015-05-28 2019-05-17 Tweed Inc. Thca合成酶表达改变的大麻植物
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP3452036A4 (en) 2016-05-04 2019-11-06 Inmed Pharmaceuticals Inc. USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND ASSOCIATED BINDING WEB DISEASES
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
SG11202001725SA (en) * 2017-09-01 2020-03-30 Pureform Global Inc Synthetic cannabidiol compositions and methods of making the same
SG11202002169TA (en) * 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
EP3684353A4 (en) * 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
US20190183849A1 (en) * 2017-10-21 2019-06-20 Alexander Kariman Compound and method for treatment of diseases and disorders
JP2021506829A (ja) * 2017-12-20 2021-02-22 漢義生物科技（北京）有限公司 美白製品の調製におけるカンナビジオールまたは大麻抽出物の用途
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
SI25373A (sl) * 2018-05-08 2018-08-31 Danijela Marković Naravna orodisperzibilna tableta
CA3103504A1 (en) * 2018-06-15 2019-12-19 CannPal Animal Therapeutics Limited Cannabinoid composition and methods of treatment using the same
WO2020051371A2 (en) * 2018-09-05 2020-03-12 Noramco, Inc. Cannabidiol compositions having modified cannabinoid profiles
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020220092A1 (en) * 2019-05-01 2020-11-05 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4037663A1 (en) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3160323A1 (en) * 2019-11-07 2021-05-14 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
WO2022006187A1 (en) * 2020-06-30 2022-01-06 Np Pharma Holdings, Llc Methods of using cannabinoid compositions for inducing and promoting sleep
CA3091622A1 (en) 2020-08-28 2022-02-28 Teresa Ann Hanlon Pain relieving formulations containing cannabis and methods of making same
WO2022159507A1 (en) * 2021-01-19 2022-07-28 Merit Therapeutics, Inc. Combination of cannabinoids with additional therapeutic agents for treating diseases or disorders
WO2026033228A1 (en) * 2024-08-08 2026-02-12 Curaleaf International Limited Formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
AU2002231970B2 (en) * 2001-02-14 2007-08-16 CNX Therapeutics Limited Mucoadhesive pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
PT1542657E (pt) * 2002-08-14 2012-02-29 Gw Pharma Ltd Formulações líquidas canabinóides para administração pela mucosa
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain

Also Published As

Publication number Publication date
ES2429406T3 (es) 2013-11-14
GB2439393B (en) 2011-05-11
PL2037902T3 (pl) 2013-12-31
EP2037902A1 (en) 2009-03-25
WO2007148094A1 (en) 2007-12-27
JP2009541479A (ja) 2009-11-26
EP2037902B1 (en) 2013-07-03
CA2656698C (en) 2015-10-13
US20100016418A1 (en) 2010-01-21
US20120245224A1 (en) 2012-09-27
JP2013241471A (ja) 2013-12-05
GB0612512D0 (en) 2006-08-02
GB2439393A (en) 2007-12-27
CA2656698A1 (en) 2007-12-27
US20190224140A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
CA2656698C (en) Cannabinoids for use in the treatment of neuropathic pain
JP6147249B2 (ja) 神経因性疼痛の治療において使用するためのカンナビノイド
GB2432312A (en) Pharmaceutical compositions for the treatment of pain
US20080139667A1 (en) Pharmaceutical Compositions For the Treatment of Disease and/or Symptoms in Arthritis
EP4725478A2 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
US10561694B2 (en) Pharmaceutical compositions containing cannabis, uses thereof and methods for improving sleep quality
US11395813B1 (en) Cannabinoids based pharmaceutical composition
US12357587B2 (en) Cannabinoid monoterpene based pharmaceutical topical composition for musculoskeletal pain
NZ618246B2 (en) Cannabinoids for use in the treatment of neuropathic pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130903

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131024

R150 Certificate of patent or registration of utility model

Ref document number: 5399898

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees